Episode 147: CEP290 mRNA Intravitreal Therapy for LCA

This week’s episode focuses on a recent publication in Nature Medicine concerning the successful use of an intravitreal oligonucleotide for a form of Leber Congential Amaurosis (LCA). First, Dr. Allen Ho, one of the authors of the paper, rejoins the program to discuss the project and its implications. Then Dr. Matthew Weed returns to offer his perspective as a ophthalmic genetics specialist on this trial compared with other modalities such as Luxturna and what it means for the future. Dr. Weed and Dr. Sridhar have no relevant financial disclosures. Dr. Ho has receieved grant funding from Pro QR.

CME Information

Release: Jan. 2, 2019; expires Jan. 2, 2022

Reviewers: Purnima Patel, MD; Shriji Patel, MD; Carl Danzig, MD

Disclosures: The physician reviewers and Academy staff report no relevant financial disclosures.

Learning Objective: Upon completion of this episode, the listener should be able to describe evolving standards of care for the management of vitreoretinal disorders or the outcomes from recent research and how these impact patient care decisions.

Audience: This activity is intended for retina subspecialists and comprehensive ophthalmologists.

Accreditation: The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Academy of Ophthalmology designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits.^TM Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hardware/Software Requirements: This learning activity requires a current web browser and speaker or headset capable of playing streaming audio.